Index S&P 500
P/E 19.09
EPS (ttm) 7.41
Insider Own 1.67%
Shs Outstand 88.82M
Perf Week 6.52%
Market Cap 12.40B
Forward P/E 13.53
EPS next Y 10.46
Insider Trans -8.84%
Shs Float 86.23M
Perf Month 4.53%
Income 691.53M
PEG 1.27
EPS next Q 1.95
Inst Own 91.68%
Short Float 4.22%
Perf Quarter 26.01%
Sales 12.14B
P/S 1.02
EPS this Y 9.81%
Inst Trans -2.64%
Short Ratio 4.43
Perf Half Y 83.12%
Book/sh 11.89
P/B 11.89
EPS next Y 12.42%
ROA 3.92%
Short Interest 3.64M
Perf Year 60.09%
Cash/sh 5.43
P/C 26.04
EPS next 5Y 15.00%
ROE 78.21%
52W Range 71.51 - 141.54
Perf YTD 35.00%
Dividend Est. -
P/FCF 8.29
EPS past 5Y 51.82%
ROI 5.93%
52W High -0.08%
Beta 0.96
Dividend TTM -
Quick Ratio 1.13
Sales past 5Y 1.27%
Gross Margin 25.33%
52W Low 97.77%
ATR (14) 3.07
Dividend Ex-Date -
Current Ratio 1.19
EPS Y/Y TTM 30.63%
Oper. Margin 13.19%
RSI (14) 69.83
Volatility 2.63% 2.10%
Employees 70000
Debt/Eq 10.53
Sales Y/Y TTM 4.57%
Profit Margin 5.70%
Recom 3.00
Target Price 131.66
Option/Short Yes / Yes
LT Debt/Eq 10.04
EPS Q/Q 173.11%
Payout 0.00%
Rel Volume 1.08
Prev Close 139.75
Sales Surprise 4.57%
EPS Surprise 14.73%
Sales Q/Q 7.85%
Earnings May 02 AMC
Avg Volume 821.40K
Price 141.43
SMA20 6.66%
SMA50 6.50%
SMA200 30.99%
Trades
Volume 166,111
Change 1.20%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-06-24 Initiated
Barclays
Equal Weight
$133
Aug-07-23 Upgrade
UBS
Neutral → Buy
$100 → $142
Nov-01-22 Downgrade
Deutsche Bank
Buy → Hold
$97 → $72
Oct-31-22 Downgrade
UBS
Buy → Neutral
$117 → $74
Aug-19-22 Resumed
UBS
Buy
$106 → $117
Jun-21-22 Reiterated
BofA Securities
Underperform
$110 → $90
Sep-10-21 Initiated
Cowen
Market Perform
$145
Aug-12-21 Downgrade
Barclays
Overweight → Equal Weight
$135 → $146
Mar-26-21 Downgrade
BofA Securities
Neutral → Underperform
$127 → $118
Jan-05-21 Downgrade
BofA Securities
Buy → Neutral
$127
Jan-24-20 Upgrade
Goldman
Neutral → Buy
$72 → $97
Nov-07-19 Downgrade
Raymond James
Outperform → Mkt Perform
Oct-25-19 Downgrade
Wolfe Research
Outperform → Peer Perform
Sep-11-19 Downgrade
William Blair
Outperform → Mkt Perform
Jul-26-19 Downgrade
Robert W. Baird
Outperform → Neutral
$70 → $65
Jan-08-19 Upgrade
UBS
Sell → Neutral
Jan-03-19 Initiated
Deutsche Bank
Buy
$60
Dec-14-18 Initiated
Barclays
Overweight
Nov-28-18 Upgrade
Raymond James
Mkt Perform → Outperform
Nov-16-18 Initiated
UBS
Sell
$64
Show Previous Ratings
May-01-24 01:04PM
10:47AM
Apr-27-24 06:10AM
Apr-25-24 05:50PM
Apr-23-24 09:00AM
07:45AM
Loading…
07:45AM
Apr-22-24 04:22PM
(Investor's Business Daily)
09:00AM
Apr-19-24 05:50PM
Apr-18-24 06:00PM
09:40AM
Apr-17-24 07:31PM
Apr-12-24 05:50PM
Apr-10-24 01:35PM
09:40AM
09:00AM
Loading…
09:00AM
09:00AM
Apr-08-24 06:00PM
Apr-02-24 09:40AM
Mar-25-24 10:59AM
10:46AM
09:40AM
Mar-24-24 05:49AM
Mar-22-24 09:52AM
Mar-21-24 12:00PM
Mar-19-24 05:10AM
Mar-15-24 09:40AM
Mar-14-24 11:30AM
Mar-11-24 04:40PM
Mar-08-24 05:20PM
09:40AM
Loading…
09:40AM
05:44AM
Mar-06-24 10:09AM
09:49AM
09:15AM
Mar-05-24 04:50PM
04:19PM
(Investor's Business Daily)
03:34PM
(The Wall Street Journal)
10:08AM
09:00AM
Feb-29-24 07:19PM
Feb-28-24 11:23PM
Feb-27-24 07:47AM
Feb-23-24 12:00PM
Feb-22-24 10:31AM
09:50AM
Feb-21-24 12:20PM
09:40AM
Feb-20-24 01:53AM
Feb-15-24 09:15AM
08:50AM
12:22AM
Feb-14-24 07:08PM
11:44AM
09:10AM
Feb-13-24 08:14PM
08:00PM
05:20PM
04:50PM
(Associated Press Finance)
04:36PM
04:08PM
Feb-12-24 06:02AM
Feb-09-24 10:51AM
06:15AM
Feb-01-24 09:40AM
Jan-31-24 03:55PM
Jan-23-24 02:00PM
Jan-22-24 09:50AM
Jan-19-24 09:40AM
Jan-16-24 09:40AM
Dec-30-23 09:26AM
04:30AM
Dec-29-23 12:34PM
Dec-26-23 09:59AM
Dec-25-23 09:40AM
Dec-19-23 10:00AM
Dec-08-23 09:40AM
Dec-07-23 11:31AM
Nov-30-23 10:00AM
Nov-28-23 06:30AM
04:03AM
Nov-27-23 11:20AM
09:07AM
Nov-22-23 10:40AM
09:40AM
Nov-15-23 11:54PM
Nov-13-23 09:31AM
(Yahoo Finance Video) +6.49%
Nov-10-23 12:00PM
Nov-09-23 09:55AM
Nov-08-23 05:46PM
12:22PM
10:56AM
07:27AM
(Thomson Reuters StreetEvents)
01:33AM
(Thomson Reuters StreetEvents)
Nov-07-23 10:07PM
08:30PM
04:44PM
04:40PM
(Associated Press Finance)
04:05PM
09:40AM
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
STAFFIERI MICHAEL DAVID Chief Operating Officer, DKC Mar 13 '24 Option Exercise 52.41 50,000 2,620,500 102,748 Mar 15 06:13 PM Rodriguez Javier Chief Executive Officer Mar 06 '24 Option Exercise 67.80 750,000 50,850,000 1,244,480 Mar 08 05:04 PM ACKERMAN JOEL CFO and Treasuer Mar 06 '24 Option Exercise 52.41 55,000 2,882,550 195,360 Mar 08 05:04 PM STAFFIERI MICHAEL DAVID Chief Operating Officer, DKC Mar 06 '24 Option Exercise 52.41 50,000 2,620,500 87,687 Mar 08 05:05 PM Rodriguez Javier Chief Executive Officer Feb 28 '24 Option Exercise 67.80 50,000 3,390,000 531,300 Feb 28 05:51 PM Rodriguez Javier Chief Executive Officer Feb 27 '24 Sale 126.87 7,397 938,467 481,300 Feb 28 05:51 PM Rodriguez Javier Chief Executive Officer Feb 26 '24 Option Exercise 67.80 450,000 30,510,000 889,002 Feb 28 05:51 PM Rodriguez Javier Chief Executive Officer Feb 26 '24 Sale 126.11 67,603 8,525,130 488,697 Feb 28 05:51 PM STAFFIERI MICHAEL DAVID Chief Operating Officer, DKC Feb 21 '24 Option Exercise 52.41 100,000 5,241,000 137,687 Feb 23 05:44 PM ACKERMAN JOEL CFO and Treasuer Feb 21 '24 Option Exercise 52.41 55,000 2,882,550 178,726 Feb 23 05:43 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off Feb 21 '24 Option Exercise 52.41 40,000 2,096,400 121,297 Feb 23 05:44 PM STAFFIERI MICHAEL DAVID Chief Operating Officer, DKC Feb 21 '24 Sale 119.81 29,488 3,533,025 37,687 Feb 23 05:44 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off Feb 21 '24 Sale 120.73 11,285 1,362,438 81,297 Feb 23 05:44 PM HEARTY JAMES O Chief Compliance Officer Feb 16 '24 Option Exercise 54.40 54,608 2,970,478 78,448 Feb 20 08:37 PM HEARTY JAMES O Chief Compliance Officer Feb 16 '24 Sale 119.64 26,164 3,130,269 20,264 Feb 20 08:37 PM Rodriguez Javier Chief Executive Officer Dec 14 '23 Option Exercise 67.80 500,000 33,900,000 833,299 Dec 18 06:44 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off Aug 22 '23 Option Exercise 52.41 40,000 2,096,400 121,297 Aug 24 06:54 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off Aug 22 '23 Sale 101.81 9,794 997,099 81,297 Aug 24 06:54 PM YALE PHYLLIS R Director May 12 '23 Option Exercise 66.29 7,165 474,968 20,275 May 12 09:31 PM YALE PHYLLIS R Director May 12 '23 Sale 95.26 2,196 209,195 13,110 May 12 09:31 PM STAFFIERI MICHAEL DAVID Chief Operating Officer, DKC May 10 '23 Option Exercise 66.29 243,994 16,174,362 348,071 May 12 09:34 PM Rodriguez Javier Chief Executive Officer May 10 '23 Option Exercise 66.29 88,213 5,847,640 403,835 May 12 09:20 PM ACKERMAN JOEL CFO and Treasuer May 10 '23 Option Exercise 66.29 56,306 3,732,525 191,097 May 12 08:44 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off May 10 '23 Option Exercise 66.29 33,784 2,239,541 135,164 May 12 09:15 PM HEARTY JAMES O Chief Compliance Officer May 10 '23 Option Exercise 66.29 26,276 1,741,836 58,835 May 12 08:48 PM DESOER BARBARA J Director May 10 '23 Option Exercise 66.29 7,165 474,968 7,165 May 12 08:46 PM NEHRA JOHN M Director May 10 '23 Option Exercise 66.29 7,165 474,968 7,165 May 12 08:50 PM Rodriguez Javier Chief Executive Officer May 10 '23 Sale 99.44 16,916 1,682,089 315,622 May 12 09:20 PM Waters Kathleen Alyce Chief Legal & Pub. Affairs Off May 10 '23 Sale 99.24 15,941 1,581,990 91,245 May 12 09:15 PM HEARTY JAMES O Chief Compliance Officer May 10 '23 Sale 101.64 5,745 583,914 32,559 May 12 08:48 PM DESOER BARBARA J Director May 10 '23 Sale 101.61 2,449 248,843 0 May 12 08:46 PM
Index NDX, S&P 500
P/E 182.38
EPS (ttm) 0.36
Insider Own 0.10%
Shs Outstand 1.25B
Perf Week 0.23%
Market Cap 81.58B
Forward P/E 9.13
EPS next Y 7.17
Insider Trans -2.00%
Shs Float 1.25B
Perf Month -7.72%
Income 484.00M
PEG 33.92
EPS next Q 1.60
Inst Own 85.76%
Short Float 1.70%
Perf Quarter -16.30%
Sales 27.42B
P/S 2.98
EPS this Y -43.56%
Inst Trans 0.85%
Short Ratio 2.85
Perf Half Y -16.70%
Book/sh 14.01
P/B 4.67
EPS next Y 88.97%
ROA 0.82%
Short Interest 21.18M
Perf Year -18.67%
Cash/sh 3.78
P/C 17.29
EPS next 5Y 5.38%
ROE 2.52%
52W Range 64.63 - 87.86
Perf YTD -19.24%
Dividend Est. 3.13 (4.79%)
P/FCF 10.99
EPS past 5Y 1.55%
ROI 1.04%
52W High -25.54%
Beta 0.22
Dividend TTM 3.02 (4.62%)
Quick Ratio 0.72
Sales past 5Y 4.16%
Gross Margin 85.17%
52W Low 1.22%
ATR (14) 1.15
Dividend Ex-Date Jun 14, 2024
Current Ratio 0.98
EPS Y/Y TTM -91.37%
Oper. Margin 34.52%
RSI (14) 30.58
Volatility 2.45% 1.70%
Employees 18000
Debt/Eq 1.47
Sales Y/Y TTM 2.13%
Profit Margin 1.77%
Recom 2.22
Target Price 83.39
Option/Short Yes / Yes
LT Debt/Eq 1.36
EPS Q/Q -517.48%
Payout 66.62%
Rel Volume 0.61
Prev Close 65.51
Sales Surprise 5.17%
EPS Surprise 11.60%
Sales Q/Q 5.66%
Earnings Apr 25 AMC
Avg Volume 7.43M
Price 65.42
SMA20 -2.84%
SMA50 -7.69%
SMA200 -14.13%
Trades
Volume 850,006
Change -0.14%
Date
Action
Analyst
Rating Change
Price Target Change
May-01-24 Reiterated
Maxim Group
Buy
$90 → $85
Apr-24-24 Upgrade
HSBC Securities
Reduce → Hold
$69
Feb-22-24 Downgrade
Truist
Buy → Hold
$91 → $82
Nov-09-23 Initiated
Deutsche Bank
Hold
$75
Sep-08-23 Upgrade
BofA Securities
Neutral → Buy
$88 → $95
Sep-06-23 Initiated
HSBC Securities
Reduce
$71
Jul-24-23 Reiterated
Barclays
Equal Weight
$81 → $80
May-16-23 Upgrade
BMO Capital Markets
Market Perform → Outperform
$90 → $100
Apr-28-23 Resumed
Piper Sandler
Overweight
$105
Jan-03-23 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$87
Dec-13-22 Resumed
BofA Securities
Neutral
$85
Dec-09-22 Downgrade
DZ Bank
Buy → Hold
$90
Oct-31-22 Upgrade
Barclays
Underweight → Equal Weight
$60 → $76
Oct-28-22 Upgrade
Truist
Hold → Buy
$76 → $91
Oct-28-22 Upgrade
Piper Sandler
Neutral → Overweight
$79 → $96
Oct-28-22 Reiterated
Wells Fargo
Equal Weight
$74 → $75
Oct-28-22 Reiterated
RBC Capital Mkts
Outperform
$79 → $82
Oct-28-22 Reiterated
JP Morgan
Overweight
$80 → $87
Oct-28-22 Reiterated
Jefferies
Buy
$78 → $86
Oct-28-22 Reiterated
Cowen
Outperform
$75 → $80
Show Previous Ratings
May-01-24 02:38PM
10:53AM
10:19AM
08:25AM
Apr-30-24 04:05PM
12:01PM
Loading…
12:01PM
Apr-29-24 09:00AM
08:18AM
06:01AM
Apr-28-24 05:50PM
Apr-26-24 04:31PM
04:10PM
(Investor's Business Daily)
11:44AM
10:45AM
10:24AM
10:09AM
Loading…
10:09AM
10:08AM
09:59AM
09:14AM
08:11AM
(Thomson Reuters StreetEvents)
08:00AM
03:35AM
Apr-25-24 09:45PM
06:00PM
05:49PM
05:41PM
05:15PM
04:59PM
04:50PM
04:40PM
(Investor's Business Daily)
04:14PM
Loading…
04:14PM
(Associated Press Finance)
04:11PM
04:07PM
(Investor's Business Daily)
04:02PM
04:02PM
Apr-22-24 01:57PM
09:16AM
Apr-19-24 05:50PM
Apr-18-24 06:33PM
06:00PM
01:45PM
10:01AM
Apr-17-24 02:03AM
Apr-16-24 09:00AM
Apr-15-24 08:00AM
01:06AM
12:22AM
Apr-12-24 06:00PM
Apr-11-24 09:15AM
Apr-10-24 06:09PM
Apr-09-24 06:15PM
02:40PM
07:37AM
Apr-08-24 04:05PM
Apr-06-24 06:49AM
Apr-05-24 08:30AM
Apr-03-24 09:00AM
Apr-02-24 06:00PM
09:15AM
Mar-28-24 08:30AM
07:00AM
06:45AM
06:45AM
Mar-26-24 09:15AM
05:15AM
Mar-25-24 06:00PM
Mar-22-24 09:18AM
Mar-20-24 09:00AM
Mar-19-24 06:00PM
09:05AM
Mar-18-24 07:29PM
08:00AM
(Investor's Business Daily)
Mar-17-24 05:20PM
08:50AM
08:15AM
Mar-15-24 06:00AM
Mar-14-24 09:38AM
Mar-13-24 06:00PM
07:03AM
Mar-12-24 08:45AM
Mar-11-24 08:24AM
08:02AM
Mar-10-24 06:35AM
Mar-07-24 05:50PM
11:31AM
07:59AM
07:15AM
Mar-06-24 04:30PM
10:25AM
09:00AM
08:00AM
06:15AM
Mar-05-24 04:35PM
04:30PM
08:45AM
07:00AM
02:56AM
Mar-01-24 05:50PM
Feb-29-24 08:30AM
06:01AM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Parsey Merdad Chief Medical Officer Apr 01 '24 Sale 72.96 2,000 145,920 96,304 Apr 02 06:38 PM Parsey Merdad Chief Medical Officer Feb 29 '24 Sale 72.74 8,230 598,624 92,706 Feb 29 06:35 PM Parsey Merdad Chief Medical Officer Feb 28 '24 Sale 73.18 2,000 146,360 100,936 Feb 29 06:35 PM GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM GILEAD SCIENCES, INC. 10% Owner Jan 29 '24 Buy 21.00 15,238,095 319,999,995 30,061,124 Jan 31 05:00 PM Dickinson Andrew D Chief Financial Officer Jan 16 '24 Sale 85.78 5,000 428,900 101,534 Jan 17 06:01 PM Mercier Johanna Chief Commercial Officer Jan 09 '24 Sale 85.23 8,242 702,466 82,729 Jan 10 03:58 PM Dickinson Andrew D Chief Financial Officer Oct 17 '23 Sale 80.00 5,000 400,017 104,003 Oct 18 04:31 PM Parsey Merdad Chief Medical Officer Sep 12 '23 Sale 76.99 1,501 115,562 70,130 Sep 13 06:50 PM Dickinson Andrew D Chief Financial Officer Jul 20 '23 Sale 80.00 5,000 400,000 107,587 Jul 21 05:30 PM GILEAD SCIENCES, INC. 10% Owner Jun 28 '23 Buy 19.26 1,010,000 19,452,600 14,823,029 Jun 30 03:12 PM GILEAD SCIENCES, INC. 10% Owner Jun 27 '23 Buy 3.75 2,930,870 10,990,762 16,635,286 Jun 28 05:17 PM Parsey Merdad Chief Medical Officer Jun 13 '23 Sale 76.90 1,485 114,197 29,402 Jun 14 05:48 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite